U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H21FN2O
Molecular Weight 324.3927
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CITALOPRAM

SMILES

CN(C)CCCC1(c2ccc(cc2)F)c3ccc(cc3CO1)C#N

InChI

InChIKey=WSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H21FN2O
Molecular Weight 324.3927
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Citalopram hydrobromide (citalopram HB) belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). It is sold under the brand name Celexa and is indicated for the treatment of depression. The mechanism of action of citalopram HBr is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Citalopram is a racemic mixture, and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer. Citalopram can be used off-label for the treatment of anxiety, autism, dementia, alcoholism, diabetic neuropathy, eating disorders such as anorexia and bulimia, premature ejaculation and many others. Citalopram causes dose-dependent QT interval prolongation which is why it isno longer prescribed at doses greater than 40 mg per day.

Originator

Sources: Bigler, Allan J., et al. 'Quantitative structure-activity-relationships in a series of selective 5-HT uptake inhibitors.' EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 12.3 (1977): 289-295.https://lakemedelsverket.se/LMF/Lakemedelsinformation/?nplid=19980626000180

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.78 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CELEXA

Approved Use

Citalopram HBr is indicated for the treatment of depression. The efficacy of citalopram HBr in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The antidepressant action of citalopram HBr in hospitalized depressed patients has not been adequately studied. The efficacy of citalopram HBr in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials (see CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use citalopram HBr for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Launch Date

9.0063359E11
Primary
Celexa

Approved Use

INDICATIONS AND USAGE. Celexa (citalopram HBr) is indicated for the treatment of depression.

Launch Date

9.0054722E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.2 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.5 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.1 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
21.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
43.7 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
65.6 ng/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.6 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
204.5 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1153.2 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
843.7 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1010.4 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2070.3 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2946.5 ng × h/mL
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
533.2 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.5 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.3 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
38.5 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
40 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
39.5 h
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
36.3 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
26%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
26%
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
26%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DESMETHYLCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
18%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Other AEs: Dizziness, Drowsiness...
Other AEs:
Dizziness (mild, 1 patient)
Drowsiness (mild, 1 patient)
Sources:
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Disc. AE: Asthenia, Nausea...
AEs leading to
discontinuation/dose reduction:
Asthenia (1%)
Nausea (4%)
Dry mouth (1%)
Vomiting (1%)
Dizziness (2%)
Insomnia (3%)
Somnolence (2%)
Agitation (1%)
Sources:
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Other AEs: Seizures, Tachycardia...
Other AEs:
Seizures (1 patient)
Tachycardia (1 patient)
Neuromuscular disorders NEC (1 patient)
Hyperthermia (severe, 1 patient)
Sources:
360 mg 1 times / day multiple, oral
Highest studied dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Other AEs: Dizziness, Sweating...
Other AEs:
Dizziness (grade 5)
Sweating
Nausea
Vomiting
Tremor
Somnolence
Sinus tachycardia
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness mild, 1 patient
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Drowsiness mild, 1 patient
800 mg single, oral
Overdose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Agitation 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Asthenia 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Dry mouth 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Vomiting 1%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Dizziness 2%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Somnolence 2%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Insomnia 3%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Nausea 4%
Disc. AE
80 mg 1 times / day steady, oral (max)
Studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: steady
Dose: 80 mg, 1 times / day
Sources:
unhealthy, 18-66 years
n = 1063
Health Status: unhealthy
Condition: depression
Age Group: 18-66 years
Sex: M+F
Population Size: 1063
Sources:
Neuromuscular disorders NEC 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Seizures 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Tachycardia 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Hyperthermia severe, 1 patient
760 mg single, oral
Overdose
Dose: 760 mg
Route: oral
Route: single
Dose: 760 mg
Sources:
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
Nausea
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sinus tachycardia
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Somnolence
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sweating
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Tremor
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Vomiting
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Dizziness grade 5
2800 mg single, oral
Overdose
Dose: 2800 mg
Route: oral
Route: single
Dose: 2800 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Selective serotonin reuptake inhibitors for late-life depression: a comparative review.
2001
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.
2001
The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers.
2001 Apr
Citalopram: a comprehensive review.
2001 Apr
Are newer antidepressants really "better tolerated"?
2001 Apr
Involvement of 5-HT(2C) receptors in the anti-immobility effects of antidepressants in the forced swimming test in mice.
2001 Apr
Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
2001 Apr
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
2001 Apr
Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care.
2001 Apr
On-line extraction using an alkyl-diol silica precolumn for racemic citalopram and its metabolites in plasma. Results compared with solid-phase extraction methodology.
2001 Apr 5
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.
2001 Aug
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.
2001 Aug
Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram.
2001 Aug 1
Some behavioural effects of antidepressant drugs are time-dependent.
2001 Feb
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management.
2001 Feb
[Depression and anxiety in the elderly still underdiagnosed. SSRI preparations in conjunction with psychotherapy provide effective treatment].
2001 Feb 21
Too much hypothalamic serotonin transporter is bad for your mood.
2001 Jan
Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats.
2001 Jan
Does interaction between zinc and glutamate system play a significant role in the mechanism of antidepressant action?
2001 Jan-Feb
Citalopram in refractory obsessive-compulsive disorder: an open study.
2001 Jul
Behavioral and neurochemical effects of anpirtoline and citalopram in isolated and group housed mice.
2001 Jul
Citalopram for OCD and Tourette's syndrome.
2001 Jul
Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor.
2001 Jul 20
Involvement of adenosine in the effect of antidepressants on glutamate and aspartate release in the rat prefrontal cortex.
2001 Jun
Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study.
2001 Jun
The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study.
2001 Jun
Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
2001 Jun
[Behavioral and neurochemical study on the mechanism of the anxiolytic effect of a selective serotonin reuptake inhibitor, a selective serotonin1A agonist and lithium carbonate].
2001 Mar
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
2001 Mar
Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study.
2001 Mar
Citalopram in mentally retarded patients with depression: a long-term clinical investigation.
2001 Mar
A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication.
2001 Mar
Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice.
2001 Mar
Lack of citalopram effect on oral digoxin pharmacokinetics.
2001 Mar
Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala.
2001 Mar
Functional consequences of 5-HT transporter gene disruption on 5-HT(1a) receptor-mediated regulation of dorsal raphe and hippocampal cell activity.
2001 Mar 15
Risk profile of SSrIs in elderly depressive patients with co-morbid physical illness.
2001 May
Does mirtazapine have a more rapid onset than SSRIs?
2001 May
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
2001 May
Alzheimer's disease and related disorders.
2001 May
Rapid determination of citalopram in human plasma by high-performance liquid chromatography.
2001 May 5
Rapid response to low dose citalopram in pathological crying.
2001 May-Jun
Trichotillomania associated with dementia: a case report.
2001 May-Jun
QTc interval prolongation associated with citalopram overdose: a case report and literature review.
2001 May-Jun
Distribution of serotonin, its metabolites and 5-HT transporters in the neostriatum of Lurcher and weaver mutant mice.
2001 Sep
Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies.
2001 Sep 1
A retrospective study of citalopram in adolescents with depression.
2001 Summer
Citalopram-induced dyskinesia of the tongue: a video presentation.
2016 Dec 23
Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment.
2017 Jan 10
Patents

Sample Use Guides

Citalopram should be administered once daily, in the morning or evening, with or without food. Citalopram should be administered at an initial dose of 20 mg once daily, with an increase to a maximum dose of 40 mg/day at an interval of no less than one week. Doses above 40 mg/day are not recommended due to the risk of QT prolongation. Additionally, the only study pertinent to dose response for effectiveness did not demonstrate an advantage for the 60 mg/day dose over the 40 mg/day dose.
Route of Administration: Oral
The cytotoxic activity of the Citalopram were evaluated in the HEK, HEK-SERT, SHSY-5Y (Neutral red assay) and DG-75 (Alamar Blue assay) cell lines. Cells were treated with the Citalopram for 48 (HEK, HEK-SERT, SHSY-5Y) or 72 (DG-75) hrs.
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:37:23 UTC 2021
Edited
by admin
on Sat Jun 26 00:37:23 UTC 2021
Record UNII
0DHU5B8D6V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CITALOPRAM
INN   MART.   MI   USP   VANDF   WHO-DD  
INN  
Official Name English
CITALOPRAM [WHO-DD]
Common Name English
CITALOPRAM [MI]
Common Name English
CITALOPRAM [MART.]
Common Name English
CITALOPRAM [VANDF]
Common Name English
CITADUR
Brand Name English
CITALOPRAM [INN]
Common Name English
CITALOPRAM [USP]
Common Name English
1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE
Common Name English
Classification Tree Code System Code
LIVERTOX 212
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
NCI_THESAURUS C265
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
NCI_THESAURUS C94725
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
WHO-VATC QN06AB04
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
NDF-RT N0000175696
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
WHO-ATC N06AB04
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
NDF-RT N0000000109
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
Code System Code Type Description
LACTMED
Citalopram
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
ECHA (EC/EINECS)
261-891-1
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
INN
4138
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
CAS
59729-33-8
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
RXCUI
2556
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
CITALOPRAM
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
DRUG CENTRAL
663
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
PUBCHEM
2771
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
EVMPD
SUB07485MIG
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
MESH
D015283
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
EPA CompTox
59729-33-8
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
MERCK INDEX
M3587
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61680
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
FDA UNII
0DHU5B8D6V
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL549
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
IUPHAR
7547
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
DRUG BANK
DB00215
Created by admin on Sat Jun 26 00:37:24 UTC 2021 , Edited by admin on Sat Jun 26 00:37:24 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC